167 related articles for article (PubMed ID: 10946875)
1. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen.
Finne P; Auvinen A; Koistinen H; Zhang WM; Määttänen L; Rannikko S; Tammela T; Seppälä M; Hakama M; Stenman UH
J Clin Endocrinol Metab; 2000 Aug; 85(8):2744-7. PubMed ID: 10946875
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
3. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
Miyata Y; Sakai H; Hayashi T; Kanetake H
Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
Chokkalingam AP; Pollak M; Fillmore CM; Gao YT; Stanczyk FZ; Deng J; Sesterhenn IA; Mostofi FK; Fears TR; Madigan MP; Ziegler RG; Fraumeni JF; Hsing AW
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):421-7. PubMed ID: 11352850
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
6. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
[TBL] [Abstract][Full Text] [Related]
7. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
[TBL] [Abstract][Full Text] [Related]
8. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F
Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
[TBL] [Abstract][Full Text] [Related]
9. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
Nam RK; Trachtenberg J; Jewett MA; Toi A; Evans A; Emami M; Narod SA; Pollak M
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1270-3. PubMed ID: 15894684
[TBL] [Abstract][Full Text] [Related]
10. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
Janssen JA; Wildhagen MF; Ito K; Blijenberg BG; Van Schaik RH; Roobol MJ; Pols HA; Lamberts SW; Schröder FH
J Clin Endocrinol Metab; 2004 Sep; 89(9):4391-6. PubMed ID: 15356036
[TBL] [Abstract][Full Text] [Related]
11. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D
Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996
[TBL] [Abstract][Full Text] [Related]
12. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
[TBL] [Abstract][Full Text] [Related]
13. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
Zhigang Z; Jieming L; Su L; Wenlu S
J Surg Oncol; 2007 Jul; 96(1):54-61. PubMed ID: 17345593
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
15. Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection.
Stattin P; Stenman UH; Riboli E; Hallmans G; Kaaks R
J Clin Endocrinol Metab; 2001 Dec; 86(12):5745-8. PubMed ID: 11739433
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score.
Correa LL; Neto LV; Lima GA; Gabrich R; Miranda LC; Gadelha MR
Int Braz J Urol; 2015; 41(1):110-5. PubMed ID: 25928516
[TBL] [Abstract][Full Text] [Related]
17. [Insulin-like growth factor (IGF-1) and the clinical course of prostate cancer, benign hyperplasia and prostatic intraepithelial neoplasia].
Povelitsa EA; Nabyrov EA
Vopr Onkol; 2008; 54(5):596-601. PubMed ID: 19069473
[TBL] [Abstract][Full Text] [Related]
18. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
Sciarra A; Gentile V; Monti S; Dattilo C; Autran Gomez A; Salciccia S; Pannunzi LP; Toscano V; Di Silverio F
Urol Int; 2008; 80(1):68-73. PubMed ID: 18204237
[TBL] [Abstract][Full Text] [Related]
19. Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?
Wolk A; Andersson SO; Mantzoros CS; Trichopoulos D; Adami HO
Lancet; 2000 Dec; 356(9245):1902-3. PubMed ID: 11130391
[TBL] [Abstract][Full Text] [Related]
20. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]